Causes and consequences of incomplete HIV RNA suppression in clinical trials

HIV Clinical Trials

Volumn 10, Issue 5, 2009, Pages 289-298

  Pozniak, Anton ^a   Gupta, Ravindra K ^b   Pillay, Deenan ^b   Arribas, Jose ^c   Hill, Andrew ^d  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

HIV clinical trials; HIV RNA; Protease inhibitors; Reverse transcriptase inhibitors

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; VIRUS RNA; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; RNA ANALYSIS; SYSTEMATIC REVIEW; VIREMIA; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, VIRAL; HIV; HIV INFECTIONS; HUMANS; RNA, VIRAL; TREATMENT OUTCOME;

EID: 70450212567     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1005-289     Document Type: Review

References (40)

1. Hammer S, Eron J, Reiss P, et al. Antiretroviral treatment of Adult HIV infection. 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300(5):555-570.
2. Gazzard BG, on behalf of the BHIVA Treatment Guidelines Writing Group. British HIV Association guidelines for the treatment of HIV-1 infected adults with antiretroviral therapy 2008. HIV Med. 2008;9:563-608.
3. Roche Diagnostics GmbH, Manhheim, Germany. COBAS Amplicor HIV-1 MONITOR Test, version 1.5. June 2007, Package Insert. Available at: http://www.fda.gov/ Cber/ sba/hiv1roc122002S.htm. Accessed September 2008.
4. Lima V, Harrigan R, Montaner J. Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay. J Acquir Immune Defic Syndr. 2009;51(1):3-6.
5. Maldarelli F, Palmer S, King M, et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viraemia. PLos Pathogens. 2007;3(4):e46.
6. Gandhi R, Zheng S, Bosch R, Chan E, Margolis D, Read S. Raltegravir (RAL) intensifi cation does not reduce low-level residual viremia in HIV-1-infected patients on antiretroviral therapy (ART): results from ACTG A5244. In: Program and abstracts from the Fifth Conference on HIV Pathogenesis, Treatment and Prevention; Cape Town, South Africa. Abstract WELBB104.
7. Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. JAMA. 2005;293(7):817-829.
8. Garcia-Gasco P, Maida I, Blanco F, et al. Episodes of lowlevel viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome. J Antimicrob Chemother. 2008;61:699-704.
9. Karlsson A, Younger S, Martin J, et al. Immunologic and virologic evolution during periods of intermittent and persistent low-level viraemia. AIDS. 2004;18(7):891-989.
10. Percus JK, Percus OE, Markowitz M, et al. The distribution of viral blips observed in HIV-1 infected patients treated with combination antiretroviral therapy. Bull Math Biol. 2003;65(2):263-277.
11. Di Mascio M, Percus JK, Percus OE, Markowitz M, Ho DD, Perelson AS. Duration of an intermittent episode of viremia. Bull Math Biol. 2005;67(4):885-900.
12. Staszewski S, Sabin C, Dauer B, Lepri A, Phillips A. Defi nition of loss of virological response in trials of antiretroviral drugs. AIDS. 2003;17:1997-1998.
13. Havlir D, Bassett R, Levitan D, et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA. 2001;286:171-179.
14. Greub G, Cozzi-Lepri A, Ledergerber B, et al. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS. 2002;16: 1967-1969.
15. Damond F, Roquebert B, Bénard A, et al. Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR version 1.5 and the Roche COBAS AmpliPrep/ COBAS TaqMan HIV-1 assays. J Clin Microbiol. 2007;45: 3436-3438.
16. Gueudin M, Plantier J, Lemee V, et al. Evaluation of the Roche COBAS TaqMan and Abbott RealTime Extraction- Quantification Systems for HIV-1 subtypes. J Acquir Immun Defic Syndr. 2007;44:500-505.
17. Walmsley S, Ruxrungtham K, Slim J, Ward D, Larson P, Raffi F. The Gemini Study saquinavir/r (SQV/r) vs lopinavir/r (LPV/r) plus emtricitabine/tenofovir (FTC/TDF) as initial therapy in HIV-1 infected patients. In: Program and abstracts from the European AIDS Clinical Society Conference; October 2007; Madrid, Spain. Abstract PS1/4.
18. Gathe J, daSilva B, Loufty M, et al. Study M05-730 primary efficacy results at week 48: phase 3, randomized, open-label study of lopinavir-ritonavir (LPV/r) tablets once-daily (OD) versus twice-daily (BID), co-administered with tenofovir (TDF) + emtricitabine (FTC) in antiretroviral naïve (ARV) HIV-1 infected subjects. In: Program and abstracts from the 15th Conference on Retroviruses and Opportunistic Infections (CROI); February 2008; Boston, MA. Abstract 775.
19. Cooper D, et al. Efficacy and safety of two doses of tipranavir/ ritonavir versus lopinavir/ritonavir-based therapy in antiretroviral-naïve patients: results of BI 1182.33. In: Program and abstracts from the Eighth International Congress on Drug Therapy in HIV Infection; Glasgow; 2006. Abstract PL13.4.
20. Riddler S, Haubrich R, DiRienzo A, et al., ACTG Study 5142 Team. Class-sparing regimens for initial treatment of HIV-1 infection. New Eng J Med. 2008;358(20):2095-2106.
21. Gupta R, Hill A, Sawyer A, Pillay D. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis. 2008;47: 712-722.
22. Von Wyl V, Yerly S, Boni S, et al. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral therapy. A comparison of different regimen types. Arch Intern Med. 2007;167(16): 1782-1790.
23. US Department of Health and Human Services, Food and Drug Administration and Center for Drug Evaluation and Research. Guidance for industry: antiretroviral drugs using plasma HIV RNA measurements-clinical considerations for accelerated and traditional approval. Available at: http://www.fda.gov/CDER/ GUIDANCE/3647fnl.pdf. Accessed August 15, 2007.
24. Molina J, Andrade-Villanueva J, Echevarria J, et al. Efficacy and safety of once-daily atazanavir-ritonavir compared to twice daily lopinavir-ritonavir, each in combination with tenofovir and emtricitabine in ARV-naïve HIV-1 infected subjects: the CASTLE study, 48 week results. In: Program and abstracts from the 15th Conference on Retroviruses and Opportunistic Infections (CROI); February 2008; Boston, MA. Abstract 37.
25. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triplenucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350(18):1850-1861.
26. Cane P, Kaye S, Smit E, et al. Genotypic antiretroviral drug resistance testing at low viral loads in the UK. HIV Med. 2008;9:673-676.
27. Pozniak A, Gazzard B, Yehya M, Pillay D. Wildfire A, Cox A. Evidence of low-level replication (<50 copies/mL) predicts eventual virologic failure. In: Program and abstracts from the 10th Conference on Retroviruses and Opportunistic Infections, February; 2006 Denver, CO. Abstract 576.
28. DeJesus E, Herrera G, Teofilo E, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral naïve HIV infected adults. Clin Infect Dis. 2004;39:1038-1046.
29. Moyle G, DeJesus E, Cahn P, et al. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral naive HIV-infected patients. J Acquir Immune Defic Syndr. 2005;38: 417-425.
30. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2000;292(2):191-201.
31. Emitricabine (Emitriva, FTC) US prescribing information. Gilead Sciences Inc; July 2003. www.emtriva.com.
32. Galant J, DeJesus E, Arribas J, et al. Tenofovir DF, emtricitabine and efavirenz vs zidovudine, lamivudine and efavirenz for HIV. N Engl J Med. 2006;354:251-260.
33. De Jesus E, McCarty D, Farthing CF, et al. Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial. Clin Infect Dis. 2004;39(3):411-418.
34. Saag M, Ive P, Heera J, et al. A multicentre, randomised, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naïve patients infected with R5 HIV1; Week 48 results of the MERIT Study. In: Program and abstracts from the Fourth IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 2007; Sydney, Australia. Abstract WESS104.
35. Ortiz R, DeJesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir-ritonavir in treatment naïve HIV-1 infected patients at Week 48. AIDS. 2008;22:1389-1397.
36. Smith K, Fine D, Patel P, et al. Efficacy and safety of abacavir/lamivudine compared to tenofovir/emtricitabine in combination with once-daily lopinavir-ritonavir through 48 weeks in the HEAT study. In: Program and abstracts from the 15th Conference on Retroviruses and Opportunistic Infections (CROI); February 2008; Boston, MA. Abstract 774.
37. Eron J, Yeni P, Gathe J, et al. The KLEAN study of fosamprenavir- ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, or initial treatment of HIV infection over 48 weeks: a randomised non- inferiority trial. Lancet. 2006;368:476-482.
38. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfi navir for the initial treatment of HIV infection. N Engl J Med. 2002;346(26):2039-2046.
39. Gathe J, Ive P, Wood R, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ ritonavir versus twice-daily nelfinavir in naïve HIV-1 infected patients. AIDS. 2004;18:1529-1537.
40. Malan N, Krantz E, Neal D, Kastango K, Frederick D, Mathew M. Efficacy and safety of atazanavir with and without ritonavir in antiretroviral-naïve subjects. BMS089: 48-week results. In: Program and abstracts from the 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, CO.